Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma
Authors:
Open Access
- 27 October 2015
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 314 (16) , 1720-1730
Abstract
National treatment recommendations suggest increasing inhaled corticosteroid (ICS) dose or adding a long-acting β-agonist (LABA) to asthma patients with poor asthma control on low-dose ICS.1,2 However, asthma experts and the US Food and Drug Administration have questioned the safety of LABA therapy,3-5 noting possible increases in serious events, including hospitalizations and death. Data suggest that LABA risks, if they exist, may disproportionately affect black populations6 and that black individuals may not benefit from LABAs to the same degree as individuals of other races.7-9 Some studies have suggested that allelic variation at the Arg16Gly locus of the β2-adrenergic receptor (ADRB2 [NCBI Entrez Gene 109690]) gene may be associated with increased rates of adverse outcomes when LABAs are used for asthma,10-12 especially among black patients.13Keywords
This publication has 18 references indexed in Scilit:
- Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic studyThe Lancet Respiratory Medicine, 2014
- Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trialThe Lancet Respiratory Medicine, 2014
- Predictors of response to tiotropium versus salmeterol in asthmatic adultsJournal of Allergy and Clinical Immunology, 2013
- Asthma Symptom Utility Index: Reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patientsJournal of Allergy and Clinical Immunology, 2012
- Faculty Opinions recommendation of Tiotropium bromide step-up therapy for adults with uncontrolled asthma.2010
- Choosing Asthma Step-up CareNew England Journal of Medicine, 2010
- Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trialThe Lancet, 2009
- Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studiesThe Lancet, 2007
- Salmeterol response is not affected by β2-adrenergic receptor genotype in subjects with persistent asthmaJournal of Allergy and Clinical Immunology, 2006
- Measurement properties and interpretation of three shortened versions of the asthma control questionnaireRespiratory Medicine, 2005